Core Viewpoint - OnKure Therapeutics is preparing to present preliminary data from its first-in-human clinical trial of OKI-219 at the 2024 San Antonio Breast Cancer Symposium, with a focus on its potential as a precision medicine in oncology [1][5]. Group 1: Company Announcements - OnKure will hold an investor call on December 10, 2024, to review preliminary data from the PIKture-01 study of OKI-219, rescheduled from December 13, 2024 [2]. - The full text of all regular abstracts from the SABCS has been published, and OnKure plans to include additional data in its poster presentations [3]. - The company is developing OKI-219 as a selective PI3KαH1047R inhibitor, targeting advanced solid tumors and advanced breast cancer [5][6]. Group 2: Poster Presentation Details - The poster titled "Preliminary results from PIKture-01, a First-in-Human Study of OKI-219" will be presented on December 12, 2024, from 12:30 PM to 2:00 PM CST [4]. - Another poster titled "OKI-219 enhances activity of SOC therapies in double and triple combinations" will also be presented on December 12, 2024, from 5:30 PM to 7:00 PM CST [4]. Group 3: Company Background - OnKure is focused on developing precision medicines that target biologically validated drivers of cancers, utilizing a structure-based drug design platform [6]. - The company aims to become a leader in targeting oncogenic PI3Kα, with multiple programs designed for optimal efficacy and tolerability [6].
OnKure Announces New Date for Upcoming Investor Call